A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes

Condition:   Genital Herpes Interventions:   Biological: mRNA-1608;   Biological: BEXSERO Sponsor:   ModernaTX, Inc. Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials